Last update Aug. 23, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dinoprostone is also known as
Dinoprostone in other languages or writings:
Main tradenames from several countries containing Dinoprostone in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 353 | daltons |
Protein Binding | 73 | % |
pKa | 4.3 | - |
Tmax | 0.5 - 1 | hours |
T½ | 0.04 - 0.1 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dinoprostone or prostaglandin E2 causes contraction of uterine muscle. It is mainly used in induction of labor and also for termination of pregnancy, missed miscarriage, hydatidiform mole, and intrauterine fetal death. Administration as vaginal or cervical gel, oral and intravenous.
At latest update no published data on excretion into breast milk were found.
Itsvery rapid removal from plasma make it highly unlikely the passage into breast milk in significant amount.
It is a natural component of breast milk (Shimizu 1992, Neu 1988, Alzina 1986, Friedman 1986, Lucas 1980) that increases in concentration in the first week postpartum. (Hawkes 1999). Prostaglandins in breast milk can protect the integrity of gastro-intestinal epithelial cells in infants. (Bedrick 1989)
The use of vaginal prostaglandin for labor induction is associated with a reduction in the percentage of breastfeeding, at the beginning, at one month and at three months. (Zanardo 2017, Jordan 2009)
Although dinoprostone can be used to inhibit lactation by reducing prolactin levels (Toppozada 1992, England 1988, Bremme 1980), it would be necessary to achieve a higher dose than that used at the time of partum for several days. (Berić 1992)
It would not be recommended to use it for relief of breast engorgement in women who are willing to breastfeed. The effect of reducing prolactin levels induced by dinoprostone only occurs during the first days postpartum. (Caminiti 1980)